Table 4.
Total ADRs for each treatment group and ADRs leading to drop out of patients before the end of the study
| ADR | Placebo | 16 mg cathine | 32 mg cathine | 53.3 mg cathine |
|---|---|---|---|---|
| Tachycardia | 2 | |||
| Palpitations | 5 | |||
| Chest pain | 2 | |||
| Hypertension | 1 | 1 | 3 | |
| Ischemia | 1 | |||
| Ventricular extrasystoles | 1 | |||
| ECG QT prolonged | 1 | |||
| Dizziness | 1 | |||
| Syncope | 1 | |||
| Headache | 1 | 1 | 1 | |
| Restlessness | 1 | 1 | 1 | 3 |
| Psychomotor hyperactivity | 1 | |||
| Sleep disorder | 1 | 1 | ||
| Depression | 1 | 1 | ||
| Panic attack | 1 | |||
| Hot flush | 3 | |||
| Dry mouth | 2 | 2 | ||
| Hyperhidrosis | 2 | |||
| Hepatic enzyme increased | 1 | |||
| Transaminases increased | 1 | |||
| GGT increased | 1 | |||
| Blood glucose increased | 1 | |||
| Hyperglycemia | 1 | |||
| Weight increased | 1 | |||
| Muscle spasms | 1 | 1 | ||
| Hypersensitivity | 1 | |||
| Leukopenia | 1 | 2 | ||
| Peripheral coldness | 1 | |||
| Constipation | 1 | |||
| Paresthesia | 1 | |||
| Thirst | 1 | |||
| Erectile dysfunction | 1 | |||
| Total reported ADRs | 9 | 11 | 14 | 26 |
| Drop outs due to an ADR | 3a | 3b | 4c | 2d |
a
1× headache, 1× depression, 1× hyperglycemia.
b
1× dizziness, 1× GGT increased, 1× hypersensitivity.
c
1× sleep disorder, 1× hot flush, 1× hepatic enzyme increased, 1× transaminases increased.
d
1× ischemia, 1× dry mouth.